Entocort CR 3mg capsules

Nchi: Uingereza

Lugha: Kiingereza

Chanzo: MHRA (Medicines & Healthcare Products Regulatory Agency)

Viambatanisho vya kazi:

Budesonide

Inapatikana kutoka:

DE Pharmaceuticals

ATC kanuni:

A07EA06

INN (Jina la Kimataifa):

Budesonide

Kipimo:

3mg

Dawa fomu:

Modified-release capsule

Njia ya uendeshaji:

Oral

Darasa:

No Controlled Drug Status

Dawa ya aina:

Valid as a prescribable product

Bidhaa muhtasari:

BNF: 01050200

Taarifa za kipeperushi

Page 1 of 6
PACKAGE LEAFLET: INFORMATION FOR THE USER
ENTOCORT
® CR 3 MG CAPSULES
budesonide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What Entocort Capsules are and what they are used for
2. What you need to know before you take Entocort Capsules
3. How to take Entocort Capsules
4. Possible side effects
5. How to store Entocort Capsules
6. Contents of the pack and other information
1. WHAT ENTOCORT CAPSULES ARE AND WHAT THEY ARE USED FOR
Entocort Capsules contain the active substance budesonide. This
belongs to a group of
medicines called ‘corticosteroids’. These are used to reduce
inflammation.
Crohn’s disease: Entocort Capsules are used to treat an inflammation
of the small bowel and
the first part of the large bowel.
Microscopic colitis: Entocort Capsules are used to treat microscopic
colitis (a disease with
chronic inflammation of the large bowel which is typically with
chronic watery diarrhoea).
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ENTOCORT CAPSULES
DO NOT TAKE ENTOCORT CAPSULES:

If you are allergic to budesonide or any of the other ingredients of
this medicine (listed in
section 6).

If you have an infection.
Do not take Entocort Capsules if any of the above apply to you. If you
are not sure, talk to
your doctor or pharmacist before taking Entocort Capsules.
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Entocort Capsules if:

You have ever had tuberculosis (TB).

You have ever had high blood pressure.

You have diabetes.

Y

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Entocort CR 3 mg Capsules
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains budesonide 3 mg
Excipient(s) with known effect:
Sucrose
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Hard gelatin capsules for oral administration with an opaque, light
grey body and
opaque, pink cap marked CIR
3MG in black radial print.
Each capsule contains budesonide 3 mg as gastro-resistant,
prolonged-release
granules.
4.1
THERAPEUTIC INDICATIONS
Crohn’s disease - Induction of remission in patients with mild to
moderate active
Crohn’s disease affecting the ileum and/or the ascending colon.
Microscopic colitis - Induction of remission in patients with active
microscopic colitis
Maintenance of remission in patients with microscopic colitis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
ADULTS
_Active Crohn’s disease_: The recommended daily dose for induction
of remission is
9 mg once daily in the morning, for up to eight weeks. The full effect
is usually
achieved within 2–4 weeks.
When treatment is to be discontinued, the dose should normally be
reduced for the last
2 to 4 weeks of therapy.
_Active Microscopic colitis_: The recommended dose is 9 mg once daily
in the morning
(corresponding to 3 capsules).
_Maintenance of Microscopic colitis: _The recommended dose is 6 mg
once daily in the
morning (corresponding to 2 capsules), or the lowest effective dose.
_ _
_Paediatric population _
There are limited data on the use of Entocort CR Capsules in children
(see Sections
5.1 and 5.2). The available data are insufficient to support safety
and efficacy in the
paediatric population, therefore such use cannot be recommended until
further data
become available.
_Older people _
No special dose adjustment is recommended. However, experience with
Entocort CR
Capsules in older people is limited.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance(s) or to any of the
excipients listed in section
6.1.
4.4
SPECIAL WARNINGS